Breaking News

Gilead to Acquire Kite Pharma for $11.9B

Gains portfolio of CAR T and TCR cell therapy candidates and manufacturing capabilities

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead Sciences has entered an agreement to acquire Kite Pharma, a cell therapy company headquartered in Santa Monica, CA, for approximately $11.9 billion. The transaction, subject to customary closing conditions, is expected to close 4Q17. Kite Pharma specializes in cell therapies, which use a patient’s own immune cells to fight cancer. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR). The ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters